From the Journals
Adults with a history of hepatocellular carcinoma had a significantly reduced risk of death after treatment of HCV infections with DAAs.
In sharp contrast with the viral hepatitis findings, mortality rates among patients with ALD and NAFLD have increased.
The SS/LS ratio is significantly higher in patients with HCV than in those with alcohol-related liver disease (ALD).
No prior authorization will be necessary for a specific combination of direct-acting antiviral agents starting July 15.
Diabetes incidence was lower in hepatitis C patients treated with DAAs than in untreated patients.
Mannose-binding lectin and ficolin-2 are potential biomarkers for the development of liver cancer in chronic HCV infection.
Large, prospective study showed direct-acting antivirals reduced mortality and cancer risk in chronic HCV-infected patients.